Literature DB >> 33402501

Tensor Regression-based Model to Investigate Heterogeneous Spatial Radiosensitivity After I-125 Seed Implantation for Prostate Cancer.

Kazuma Kobayashi1,2,3, Naoya Murakami4, Kana Takahashi4, Koji Inaba4, Hiroshi Igaki4, Ryuji Hamamoto5,2,3, Jun Itami4.   

Abstract

BACKGROUND/AIM: We established a data-driven method for extracting spatial patterns of dose distribution associated with radiation injuries, based on patients with prostate cancer who underwent iodine-125 (I-125) seed implantation. PATIENTS AND METHODS: Seventy-five patients underwent I-125 seed implantation for prostate cancer. We modeled the severity of lower urinary tract symptoms (LUTS) to be estimated using a linear model, which is formulated as an inner product between the dose distribution D and voxel-wise radiosensitivity B inside the prostate. For the estimation, tensor regression based on a low-rank decomposition with generalized fused lasso penalty was applied.
RESULTS: The spatial distribution of B was visually assessed. Positive parameters appeared dominantly in the region close to the urethra and the prostate base.
CONCLUSION: Our tensor regression-based model can predict intra-organ radiosensitivity in a data-driven manner, providing a compelling parameter distribution associated with the development of LUTS after I-125 seed implantation for prostate cancer. Copyright
© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Prostate cancer; anatomical standardization; brachytherapy; heterogeneous intra-organ radiosensitivity; tensor regression

Mesh:

Substances:

Year:  2021        PMID: 33402501      PMCID: PMC7880750          DOI: 10.21873/invivo.12283

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  28 in total

1.  The ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer.

Authors:  Philippe Lambin; Steven F Petit; Hugo J W L Aerts; Wouter J C van Elmpt; Cary J G Oberije; Maud H W Starmans; Ruud G P M van Stiphout; Guus A M S van Dongen; Kristoff Muylle; Patrick Flamen; André L A J Dekker; Dirk De Ruysscher
Journal:  Radiother Oncol       Date:  2010-07-19       Impact factor: 6.280

2.  Urinary and Rectal Toxicity Profiles After Permanent Iodine-125 Implant Brachytherapy in Japanese Men: Nationwide J-POPS Multi-institutional Prospective Cohort Study.

Authors:  Toshio Ohashi; Atsunori Yorozu; Shiro Saito; Nobumichi Tanaka; Norihisa Katayama; Shinsuke Kojima; Shinichiro Maruo; Takashi Kikuchi; Takushi Dokiya; Masanori Fukushima; Hidetoshi Yamanaka
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-05-15       Impact factor: 7.038

3.  Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry.

Authors:  Marion P R Van Gellekom; Marinus A Moerland; Marco Van Vulpen; Harm K Wijrdeman; Jan J Battermann
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-06-20       Impact factor: 7.038

4.  Segmental urethral dosimetry and urinary toxicity in patients with no urinary symptoms before permanent prostate brachytherapy.

Authors:  Carys Thomas; Mira Keyes; Mitchell Liu; Veronika Moravan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-18       Impact factor: 7.038

5.  Factors influencing urinary symptoms 10 years after permanent prostate seed implantation.

Authors:  Nelson N Stone; Naamit Kurshan Gerber; Seth Blacksburg; Jonathan Stone; Richard G Stock
Journal:  J Urol       Date:  2011-11-23       Impact factor: 7.450

6.  A tensor-based population value decomposition to explain rectal toxicity after prostate cancer radiotherapy.

Authors:  Juan David Ospina; Frédéric Commandeur; Richard Ríos; Gaël Dréan; Juan Carlos Correa; Antoine Simon; Pascal Haigron; Renaud de Crevoisier; Oscar Acosta
Journal:  Med Image Comput Comput Assist Interv       Date:  2013

7.  Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy.

Authors:  Scott G Williams; Jeremy L Millar; Gillian M Duchesne; Michael J Dally; Peter L Royce; Ross M Snow
Journal:  Radiother Oncol       Date:  2004-10       Impact factor: 6.280

8.  Urethral dose and increment of international prostate symptom score (IPSS) in transperineal permanent interstitial implant (TPI) of prostate cancer.

Authors:  Naoya Murakami; Jun Itami; Kae Okuma; Hiroshi Marino; Keiichi Nakagawa; Tsukasa Ban; Moritoshi Nakazato; Kazuyoshi Kanai; Kuniji Naoi; Masashi Fuse
Journal:  Strahlenther Onkol       Date:  2008-10-01       Impact factor: 3.621

9.  Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.

Authors:  Mira Keyes; Stacy Miller; Veronika Moravan; Tom Pickles; Michael McKenzie; Howard Pai; Mitchell Liu; Winkle Kwan; Alexander Agranovich; Ingrid Spadinger; Vincent Lapointe; Ross Halperin; W James Morris
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-12-26       Impact factor: 7.038

10.  Dose to the bladder neck is the most important predictor for acute and late toxicity after low-dose-rate prostate brachytherapy: implications for establishing new dose constraints for treatment planning.

Authors:  Lara Hathout; Michael R Folkert; Marisa A Kollmeier; Yoshiya Yamada; Gil'ad N Cohen; Michael J Zelefsky
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-10-01       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.